[
    "ile another publications other than these documents describe various compounds, they do not describe 1,4-benzothiazepine derivatives as in the present invention.</p>On the other hand, Japanese Patent Laid-Open Publication No. Hei 04-230681 (International Publication No. WO92/12148, European Patent No. 565721, U.S. Pat. No. 5,416,066) describes 1,4-benzothiazepine derivatives or pharmaceutically acceptable salts represented by the following formulas and a manufacturing method thereof. <img id=\"EMI-C00007\" path=\"US06506745-20030114-C00007.TIF\" file=\"https://surechembl.org/api/assets/attachment/59067282/US/20030114/B1/000006/50/67/45/US06506745-20030114-C00007.TIF\"/></p>[wherein R represents a hydrogen atom or lower alkoxy group having 1 to 3 carbon atoms; R<sup>1 </sup>represents a hydrogen atom, lower alkoxy group having 1 to 3 carbon atoms, or substituted phenyl group (wherein the substituent is a hydroxyl group or lower alkoxy group having 1 to 3 carbon atoms), <img id=\"EMI-C00008\" path=\"US06506745-20030114-C00008.TIF\" file=\"https://surechembl.org/api/assets/attachment/59067281/US/20030114/B1/000006/50/67/45/US06506745-20030114-C00008.TIF\"/></p>(wherein R<sup>2 </sup>represents an acyl group); X represents an oxygen atom or H2; n represents an integer of 1 or 2; and Ph represents a phenyl group.]</p>According to the Japanese Patent Laid-Open Publication No. Hei 04-230681, it is described that there are two patterns of necrosis [Static cell death (SD) and Kinetic cell death (KD)] in myocardium of cardiac infarction patients and the major cell death in human cardiac infarction is classified into the KD. It is also described that the invented compounds have an excellent KD suppression effect. However, in this document, no description is included which suggests a certain application as therapeutic agents for atrial fibrillation treatment.</p>DISCLOSURE OF INVENTIONIt is an object of the present invention to provide a therapeutic agent for atrial fibrillation treatment to mammals including human.</p>It is another object of the present invention to provide a method of treating atrial fibrillation to mammals including human.</p>As a result of a continuous research for achieving the above objects, the inventors have found out that a compound represented by the following formula [I] is amazingly excellent in anti-atrial fibrillation effects, and have completed the present invention.</p>The present invention is directed to a therapeutic agent for atrial fibrillation treatment, comprising a compound represented by the following formula [I] as an active component. The details will be shown as the following (1) to (7).</p>(1) A medical composition for atrial fibrillation treatment comprising a compound represented by the formula [I]:</p>Formula [I]<img id=\"EMI-C00009\" path=\"US06506745-20030114-C00009.TIF\" file=\"https://surechembl.org/api/assets/attachment/59067278/US/20030114/B1/000006/50/67/45/US06506745-20030114-C00009.TIF\"/></p>[wherein R<sup>1 </sup>represents a hydrogen atom or lower alkoxy group; R<sup>2 </sup>represents a hydrogen atom, lower alkoxy group or phenyl group (the phenyl group may be substituted with 1 to 3 substituents selected fro"
]